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Folliculitis decalvans is a rare neutrophilic inflam-
mation of the scalp, characterized by painful follic-
ular papules, pustules, crusting, and tufting of hairs.
It results in the destruction of hair follicles and finally
in cicatricial alopecia. The precise pathophysiology
remains vague; inherited immune abnormalities
and staphylococcal superantigens are presumed
causes. The latter rationalizes the use of conven-
tional antimicrobial treatments, such as prolonged
antibiotics and dapsone, and of anti-inflammatory
drugs as part of the therapeutic armamentarium.1
However, unclear etiology makes treatment of re-
fractory folliculitis decalvans challenging.
Apremilast is approved for the treatment of pso-
riasis and Behçet disease, both characterized by
neutrophilic inflammation. It acts as a selective
intracellular inhibitor of phosphodiesterase 4 to
regulate the production of multiple inflammatory
mediators.
CASE REPORT
A 28-year-oldman, originally from Iraq, presented
at our clinic with a 5-year history of painful folliculitis
decalvans. We observed large oval patches of hair
loss with erythema, follicular pustules, crusting, and
hair tufts distributed along the scalp, with a cutis
verticis gyrata (Fig 1, A). The clinical diagnosis was
confirmed by histology (Fig 2). Swabs from pustules
showed moderate presence of Staphylococcus
aureus and Citrobacter koseri. A deep mycosis was
excluded clinically and by histology. The patient
did not report past or present signs of acne and
hidradenitis suppurativa. Treatments with topicalepartment of Dermatology, University Hospital of Bern,
ital.
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oc@bluewin.ch.corticosteroids, antibiotics and dapsone gel, and
systemic rifampicin combined with clindamycin,
lymecyclin, dapsone, and isotretinoin failed; also,
photodynamic light therapy and adalimumab, inter-
mittently together with systemic corticosteroids,
were ineffective. Remaining off-label treatment
options—namely, interleukin (IL) 17 inhibitors—as
well as radiotherapy were relegated as last options,
considering costs and, respectively, the possible
secondary effects and definite scarring of the whole
scalp after irradiation. Apremilast in monotherapy
was subsequently initiated as for treatment of psori-
asis, supported only by shampooing with 2% chlor-
hexidine at the patient’s discretion.
Rapid and continuous improvement of the in-
flammatory lesions and of the pain was reported
within the first few days by the patient. Clinical
control after 3 weeks showed a nearly complete
remission (Fig 1, B). By then, pain and itching had
subjectively ceased completely. Clinical remission
was ascertained by the nearly complete resolution of
erythema and of all follicular pustules, oozing, and
crusts. This was underlined by trichoscopy, with
abolition of any follicular hyperkeratosis and peri-
follicular erythema; tufted hairs, hair diameter di-
versity, cicatricial white patches, and yellow dots did
not change significantly.2 Because this treatment had
no insurance coverage, therapy was discontinued
after 7 weeks, resulting in a rapid flareup. OnJAAD Case Reports 2020;6:1079-81.
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Fig 1. A, Oval patches of hair loss with erythema, follicular pustules, crusting, and hair tufts
distributed along the scalp. B, Three weeks and 4 months after start of apremilast, with nearly
complete regression of the inflammation.
Fig 2. A and B, Mostly superficial perifolliculitis with a mixed infiltrate composed of
neutrophils, plasma cells, and eosinophils in a top-heavy pattern.
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last monotherapy was resumed, with repeated
prompt and full remission that continues (now
[25 weeks).DISCUSSION
We present a patient with conventional therapy-
refractory folliculitis decalvans, successfully treated
with apremilast only. Because interruption of
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F€assler et al 1081treatment and resumption of therapy resulted in
recurrence and renewed remission, respectively, it is
likely that apremilast suppressed the inflammatory
reaction in folliculitis decalvans. The pathogenesis of
this disease is not fully understood. Staphylococcus
is thought to have a direct or indirect pathogenic
role in the etiology and may be responsible for
the dominant neutrophilic inflammatory infiltrate. A
defective immune system also increases the risk of
folliculitis decalvans, with several familial cases
reported. Mechanical factors and structural abnor-
malities, such as the plicate scalp in this patient, may
play an additional role.
T cells (CD31 and CD41), intercellular adhesion
molecule 1, interferon gamma, and IL-4 and -8 are
upregulated in folliculitis decalvans, being respon-
sible for the neutrophil migration into the dermis.
Gradually, fibroblast growth factor and transform-
ing growth factor beta also become upregulated
and are thought to mediate the scarring reaction.3-5
Apremilast, as a specific phosphodiesterase 4 in-
hibitor, suppresses innate and adaptive immune
cells, including neutrophils and T cells. Reduced
generation of spontaneous reactive oxygen species
and of neutrophilic extracellular traps was observed
in rheumatoid arthritis patients treated with apre-
milast.6 Apremilast also leads to downregulation of
various proinflammatory cytokines, including inter-
feron gamma, tumor necrosis factor a, and IL-6, -8,
-12, -17, and -23, and to the upregulation of
immunomodulatory cytokines such as IL-10.7 The
inhibition of phosphodiesterase 4 therefore alters
the cytokine composition and generates an anti-
inflammatory state, likely leading to control of the
inflammation. Because neutrophils are the predom-
inant inflammatory cell in folliculitis decalvans, the
inhibitory effect of apremilast on neutrophil activitycould explain the rapid beneficial effect observed in
this case.6
To our knowledge, this is the first report of a
successful therapy of folliculitis decalvans with
phosphodiesterase 4 inhibition; after prolonged
treatment, a taper of apremilast will show whether
full remission is possible in this patient who did not
respond to conventional therapies. The rapid effec-
tiveness of phosphodiesterase 4 inhibition intro-
duces new therapeutic options for folliculitis
decalvans and warrants further investigation.
Prospective studies with bigger patient cohorts will
verify the eventual general value of apremilast for
folliculitis decalvans.REFERENCES
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